Alantra advises Prescient Healthcare Group on investment from Bridgepoint Development Capital

Jan 2021

Sell-side advisory

Alantra, the independent global mid-market investment banking firm, has advised the shareholders of Prescient Healthcare Group (Prescient), a global product strategy advisory firm serving the pharmaceutical and biotech industries, on an investment by Bridgepoint Development Capital, replacing current investor Baird Capital as the majority shareholder.

Founded in 2007, Prescient is headquartered in London and has offices in the US, India and China. The business provides product strategy services to help its clients make better clinical and commercial decisions, resulting in enhanced outcomes for patients. Prescient works with many of the leading multinational pharmaceutical companies, as well as a growing number of emerging biotech and specialty pharmaceutical organizations. Prescient has formed a partnership with Bridgepoint to support the continued scaling of its talent platform, client value proposition and global infrastructure.

Alantra’s Healthcare team have known Prescient for many years. They were appointed due to their significant experience of working with pharma services businesses and record of identifying strategic partners and delivering investment solutions. Their role encompassed advising the shareholders on the options available to support the next stage of Prescient’s growth, designing the deal process, identifying and educating potential partners and supporting the team to enable an efficient process through to completion. 

“We are thrilled to be partnering with Bridgepoint, which has an impressive track record supporting the scaling of people-based businesses. Bridgepoint buys into our mission of becoming the biopharma strategy partner most respected for its people, expertise and impact,” said Jamie Denison-Pender, Prescient CEO. “I’m excited by the collaborative approach and hunger for excellence that Bridgepoint will bring to the boardroom and much look forward to our partnership as we continue to invest in our passion for helping our amazing clients develop and commercialize innovative treatments that bring such hope and relief to patients globally.”

Squire Patton Boggs (Mark Yeo) was the legal advisor to Prescient Healthcare Group’s shareholders.